Back to Search
Start Over
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy
- Source :
- Journal of Infection. 65:180-183
- Publication Year :
- 2012
- Publisher :
- Elsevier BV, 2012.
-
Abstract
- We describe a case of an anti-HBs-positive patient who experienced hepatitis B reactivation 18 months after the discontinuation of rituximab and after 12 months of lamivudine prophylaxis. The patient carried a hepatitis B genotype D virus harbouring a single immune escape mutation, sT118K. No consensus guidelines regarding the optimal length of treatment or the best elective drug have been defined for antiviral prophylaxis for HBsAg-negative, anti-HBc- and/or anti-HBs-positive patients undergoing immunosuppressive treatment. Screening based on HBV serological markers and HBV DNA testing is a critical issue to recognise hepatitis B reactivation as early as possible. Furthermore, it is of outstanding importance to identify alternative markers (e.g. cccDNA, HBV core related antigen, etc.), that could be predictive of HBV reactivation.
- Subjects :
- Microbiology (medical)
Hepatitis B virus
Mutation, Missense
medicine.disease_cause
Antiviral Agents
Chemoprevention
Virus
Antibodies, Monoclonal, Murine-Derived
Drug Therapy
medicine
Humans
Hepatitis B Antibodies
Aged
biology
business.industry
virus diseases
Lamivudine
cccDNA
Hepatitis B
Settore MED/07 - Microbiologia e Microbiologia Clinica
medicine.disease
Virology
digestive system diseases
Discontinuation
Infectious Diseases
Withholding Treatment
Immunology
biology.protein
Female
Virus Activation
Rituximab
Antibody
business
medicine.drug
Subjects
Details
- ISSN :
- 01634453
- Volume :
- 65
- Database :
- OpenAIRE
- Journal :
- Journal of Infection
- Accession number :
- edsair.doi.dedup.....2c620a7fdce76e8603bfcf510772f14b